Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ramnik Xavier, M.B.,B.Ch.

Co-Author

This page shows the publications co-authored by Ramnik Xavier and Ashwin Ananthakrishnan.
Connection Strength

7.896
  1. Use of Narrative Concepts in Electronic Health Records to Validate Associations Between Genetic Factors and Response to Treatment of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020 07; 18(8):1890-1892.
    View in: PubMed
    Score: 0.853
  2. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. . 2017 May 10; 21(5):603-610.e3.
    View in: PubMed
    Score: 0.730
  3. Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Nov; 21(11):2507-14.
    View in: PubMed
    Score: 0.657
  4. Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases. Inflamm Bowel Dis. 2014 May; 20(5):783-9.
    View in: PubMed
    Score: 0.592
  5. Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol. 2014 Mar; 109(3):395-400.
    View in: PubMed
    Score: 0.580
  6. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis. 2013 Aug; 19(9):2021-30.
    View in: PubMed
    Score: 0.562
  7. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther. 2013 Sep; 38(5):522-30.
    View in: PubMed
    Score: 0.560
  8. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. 2021 Aug 11; 29(8):1294-1304.e4.
    View in: PubMed
    Score: 0.244
  9. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis. 2020 09 18; 26(10):1524-1532.
    View in: PubMed
    Score: 0.230
  10. Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 03; 19(3):519-527.e5.
    View in: PubMed
    Score: 0.222
  11. The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. Elife. 2019 01 22; 8.
    View in: PubMed
    Score: 0.205
  12. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis. 2018 07 12; 24(8):1840-1848.
    View in: PubMed
    Score: 0.198
  13. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. J Crohns Colitis. 2018 Apr 27; 12(5):525-531.
    View in: PubMed
    Score: 0.195
  14. Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. Dig Dis Sci. 2018 03; 63(3):738-745.
    View in: PubMed
    Score: 0.192
  15. Genetic risk factors for serious infections in inflammatory bowel diseases. Scand J Gastroenterol. 2017 May; 52(5):570-576.
    View in: PubMed
    Score: 0.179
  16. Erratum to: Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci. 2017 02; 62(2):552.
    View in: PubMed
    Score: 0.179
  17. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci. 2017 01; 62(1):197-206.
    View in: PubMed
    Score: 0.176
  18. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. Am J Gastroenterol. 2016 12; 111(12):1816-1822.
    View in: PubMed
    Score: 0.174
  19. Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. Inflamm Bowel Dis. 2016 09; 22(9):2149-57.
    View in: PubMed
    Score: 0.174
  20. Genetic basis of TNF-a antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016 Mar; 43(6):697-704.
    View in: PubMed
    Score: 0.167
  21. Early life environment and natural history of inflammatory bowel diseases. BMC Gastroenterol. 2014 Dec 16; 14:216.
    View in: PubMed
    Score: 0.155
  22. Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell. 2019 07 25; 178(3):714-730.e22.
    View in: PubMed
    Score: 0.053
  23. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019 05; 569(7758):655-662.
    View in: PubMed
    Score: 0.053
  24. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA. 2019 02 26; 321(8):773-785.
    View in: PubMed
    Score: 0.052
  25. IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. Inflamm Bowel Dis. 2018 09 15; 24(10):2247-2257.
    View in: PubMed
    Score: 0.050
  26. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat Microbiol. 2018 03; 3(3):337-346.
    View in: PubMed
    Score: 0.048
  27. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 2017 Nov 28; 9(1):103.
    View in: PubMed
    Score: 0.047
  28. Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. Inflamm Bowel Dis. 2017 01; 23(1):82-88.
    View in: PubMed
    Score: 0.045
  29. Erratum: A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun. 2016 09 13; 7:12869.
    View in: PubMed
    Score: 0.044
  30. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun. 2016 08 09; 7:12342.
    View in: PubMed
    Score: 0.043
  31. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology. 2016 10; 151(4):724-32.
    View in: PubMed
    Score: 0.043
  32. Metagenomic Characterization of Microbial Communities In Situ Within the Deeper Layers of the Ileum in Crohn's Disease. Cell Mol Gastroenterol Hepatol. 2016 Sep; 2(5):563-566.e5.
    View in: PubMed
    Score: 0.043
  33. Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci. 2016 09; 61(9):2627-35.
    View in: PubMed
    Score: 0.043
  34. Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. Inflamm Bowel Dis. 2015 Oct; 21(10):2304-2310.
    View in: PubMed
    Score: 0.041
  35. SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. J Crohns Colitis. 2014 Aug; 8(8):845-51.
    View in: PubMed
    Score: 0.036
  36. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 01; 491(7422):119-24.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.